CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点阻断（ICB）疗法在抗癌治疗中引发了显著转变。在卵巢癌（OC）患者中已观察到对ICB的持久临床抗肿瘤活性。然而，仅有一部分患者能从中获得临床获益，且ICB治疗引起的免疫相关不良事件（irAEs）可能导致永久性组织损伤甚至致命后果。因此，亟需开发预测性生物标志物以优化患者预后并最小化毒性风险。在此，我们综述了当前用于OC检查点免疫治疗的预测性和预后性生物标志物，并重点介绍了指导ICB治疗的新兴生物标志物。进一步讨论了常见的生物标志物，如PD-L1表达状态、TIL（肿瘤浸润淋巴细胞）、突变负荷和免疫基因特征。我们提供了关于检查点免疫治疗预后和预测性生物标志物的最新综述，并为指导精准免疫治疗提供了有价值的信息。
Immune checkpoint blockade (ICB) therapy has evoked a prominent shift in anticancer therapy. Durable clinical antitumor activity to ICB has been observed in patients with ovarian cancer (OC).
However, only a subset of patients derive clinical benefit, and immune-related adverse events (irAEs) caused by ICB therapy can lead to permanent tissue damage and even fatal consequences. It is thus urgent to develop predictive biomarkers to optimize patient outcomes and minimize toxicity risk.
Herein, we review current predictive and prognostic biomarkers for checkpoint immunotherapy in OC and highlight emerging biomarkers to guide treatment with ICB. The prevalent biomarkers, such as PD-L1 expression status, tumor-infiltrating lymphocytes, mutational burden, and immune gene signatures, are further discussed.
We provide a state-of-the-art survey on prognostic and predictive biomarkers for checkpoint immunotherapy and offer valuable information for guiding precision immunotherapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
